Featured Speakers

  • Peter BrownPrincipal Investigator, Epigenetic Chemical Probes SGC

  • Richard ChesworthExecutive Director, Molecular Discovery Epizyme

  • Keith DionneCEO Constellation Pharmaceuticals

  • Jonathan NorthrupCEO Salarius Pharmaceuticals

Epigenetic drug discovery is exploding across the industry

The 5th Annual EpiCongress, Boston is a premier networking, interactive and solution-led conference that addresses how understanding the mechanisms behind genome regulation and chromatin function can help provide new therapies.

This is a meeting where you will discover industry-defining information, and expand your network to achieve effective application of epigenetic science and ensure the success of your current and future drug candidates.

Download the Brochure

Organizations that attended last year:

Why Should You Attend?

Understanding  the epigenetic mechanisms involved in a cells transformation will have a significant impact on disease prevention, diagnosis and therapy. 

EpiCongress Boston will ensure you develop a cutting edge understanding for making clinically relevant predictions and tap into the potential of epigenetics to generate new epigenetic therapies:

  • Learn about genome regulation to explore the therapeutic opportunities in altered epigenomic states
  • Explore the biology and pharmacological properties behind chromatin modifying compounds 
  • Get an insight into unpublished data from the industry's exciting clinical programs
  • Understand the chemistry behind LSD1 histone methyltransferases and demethylases to develop potent and specific small molecule inhibitors
  • Improve your target validation by identifying which inhibitors are ticking all the boxes for pharma
  • Choose the most effective biomarker strategies for your program and discuss what clinical biomarkers will look like for novel epigenetic drugs
  • Discover how companies are currently selecting their PK/PD endpoints and designing their clinical trials
  • Learn from those who have achieved successful patient selection so far in Phase I and II trials 


Led by: Daniel Vitt, CSO, 4SC & Hella Kohlhof, Manager, Translation Pharmacology, 4SC